Clinical portrait of patients with hypertrophic cardiomyopathy from age-related aspects


DOI: https://dx.doi.org/10.18565/therapy.2019.4.35-42

Krylova N.S., Maslova M.Yu., Kovalevskaya Е.А., Poteshkina N.G., Selivanova G.B.

1) N.I. Pirogov Russian National research medical University of the Ministry of Healthcare, Moscow; 2) City clinical hospital No 52 of Moscow Department of Healthcare
The management of patients with hypertrophic cardiomyopathy (HCM) depends on age characteristics.
Objective: to study the course of HCM in patients of different ages.
Material and methods. 250 patients with HCM were divided into groups: I – young age (up to 44 years) – 12.4% of patients; II – average (45–59 years) – 37.2%; III – elderly (60–74 years) – 36%; IV – senile (≥75 years) – 14,4%.
Results. Men (84%) prevailed among young patients, women (67%) – in old age. The incidence of hypertension (r=0.33; p<0.000002) and coronary artery disease (CAD) (r=0.22, p<0.009) in HCM patients increased with age with the increase of functional class of chronic heart failure (CHF) by NYHA (r=0.32, p<0.000006). The thickness of IVS did not change with age with the increase of the LV posterior wall thickness. The volume of left atrium, pulmonary hypertension degree and atrial fibrillation (AF) frequency increased (r=0,3, p=0,0004).
Conclusion. With increasing age HCM patients are characterized by the predominance of women, the increase of frequency of hypertension, CAD and AF with CHF progression.
Keywords: middle age, young age, elderly age, hypertrophic cardiomyopathy
Read entire article

Literature


  1. Gersh B.J., Maron B.J., Bonow R.O. et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary. J. Thorac. Cardiovasc. Surg. 2011; 142: 1303–38.

  2. Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35: 2733–79.

  3. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34: 2159–2219.

  4. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery. Eur Heart J. 2013; 34: 2949–3003.

  5. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016; 37(27): 2129–2200.

  6. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults. Circulation. 1995; 92: 785–89.

  7. Semsarian Ch., Maron M.S., Maron B.J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2015; 65: 1249–54.

  8. Maron B.J., Casey S.A., Haas T.S. et al. Hypertrophic cardiomyopathy with longevity to 90 years or older. American Journal of Cardiology. 2012; 109(9): 1341–47.

  9. Полякова А.А., Баранова Е.И., Семернин Е.Н. и соавт. Гендерные различия клинического течения и ремоделирования сердца при идиопатической гипертрофической кардиомиопатии в пожилом возрасте. Российский кардиологический журнал. 2018; 2: 13–18.

  10. Полякова А.А. Особенности клинического течения и генетические детерминанты гипертрофической кардиомиопатии в пожилом возрасте. Дис. … канд. мед. наук. Национальный медицинский исследовательский центр имени В.А. Алмазова. С.-П., 2018. 47–48 с.

  11. Olivotto I., Cecchi F., Poggesi C., Yacoub M.H. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012; 5: 535–46.

  12. Geske J.B., Ong K.C., Siontis K.C. et al. Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J. 2017; 38(46): 3434–40.

  13. Gurgen D., Hegner B., Kusch A. et al. Estrogen receptor-beta signals left ventricular hypertrophy sex differences in 20 normotensive deoxycorticosterone acetate-salt mice. Hypertension. 2011; 57: 648–54.

  14. Агеев Ф.Т., Габрусенко С.А., Постнов А.Ю. и др. Клинические рекомендации по диагностике и лечению кардиомиопатий (гипертрофическая). Евразийский кардиологический журнал. 2014; 3: 5–23.

  15. Maron B.J., Ethan J. et al. Risk Stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age. Circulation. 2013; 127: 585–93.

  16. Shin Y.J., Lee J.H., Yoo J.Y., Kim J.A., Jeon Y., Yoon Y.E., Chun E J. Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. European Radiology. Eur Radiol. 2019 Feb 2. doi: 10.1007/s00330-018-5951-8. [Epub ahead of print]

  17. Shin D.G., Son J-W., Park J.Y., Choi J.W., Ryu S.K. Impact of coronary artery anatomy on clinical course and prognosis in apical hypertrophic cardiomyopathy: analysis of coronary angiography and computed tomography. Korean Circ J. 2015; 45(1): 38–43.

  18. Melacini P., Basso C., Angelini A. et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010; 31: 2111–23.

  19. Полякова А.А., Гудкова А.Я., Крутиков А.Н. и др. Гипертрофическая кардиомиопатия в старшей возрастной группе: влияние факторов кардиометаболического риска и полиморфизма гена MADD. Артериальная гипертензия. 2018; 24(1): 29–40.

  20. Maron B., Rowin E., Caseyetal S. What do patients with hypertrophic cardiomyopathy die from? Am. J. Cardiol. 2016; 117: 434–35.


About the Autors

Natalia S. Krylova, PhD, associate professor of the Department of general therapy of Continuous professional education Faculty of N.I. Pirogov Russian scientific medical University of the Ministry of Healthcare of Russia, physician of functional diagnostics of City clinical hospital No 52 of Moscow Department of Healthcare. Address: 123182, Moscow, 3 Pekhotnaya str. Tel.: +7 (903) 660-31-68. E-mail: krylova_n@list.ru
Maria Yu. Maslova, candidate of the Department of general therapy of Continuous professional education Faculty of N.I. Pirogov Russian scientific medical University of the Ministry of Healthcare of Russia. Address: 123182, Moscow, 3 Pekhotnaya str. Tel.: +7 (916) 954-96-20. E-mail: m.unoemezzo@gmail.com
Elena A. Kovalevskaya, cardiologist, the Head of the Department of cardiology for patients with myocardial infarction of City clinical hospital No 52 of Moscow Department of Healthcare. Address: 123182, Moscow, 3 Pekhotnaya str.
Tel.: +7 (905) 742-72-11. E-mail: tolyaaa@mail.ru
Natalia G. Poteshkina, MD, professor, the Head of the Department of general therapy of Continuous professional education Faculty of N.I. Pirogov Russian scientific medical University of the Ministry of Healthcare of Russia, therapist, consultant of City clinical hospital No 52 of Moscow Department of Healthcare. Address: 123182, Moscow, 3 Pekhotnaya str. Tel.: +7 (910) 442-22-16. E-mail: nat-pa@yandex.ru
Galina B. Selivanova, MD, professor of the Department of general therapy of Continuous professional education Faculty of N.I. Pirogov Russian scientific medical University of the Ministry of Healthcare of Russia. Address: 123182, Moscow, 3 Pekhotnaya str. Tel.: +7 (915) 293-83-29. E-mail: galina.selivanova@rambler.ru


Similar Articles

Back to Content

Бионика Медиа